Jan 29, 2020
DelMar Pharmaceuticals Announces Peer-Reviewed Publication of Interim Results of Phase 2 Clinical Trial of VAL-083 As First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma Multiforme
Jan 13, 2020
Rigel Pharmaceuticals Provides Business Update
Jan 09, 2020
Rigel to Present at the 38th Annual J.P. Morgan Healthcare Conference
Dec 18, 2019
GSK announces positive headline results in phase 3 study of Benlysta in patients with lupus nephritis
Dec 17, 2019
Rigel Announces Chief Commercial Officer Transition
Dec 07, 2019
Oncopeptides Presents Updated Efficacy and Safety Data from Pivotal Phase 2 HORIZON Study in Patients With RRMM at ASH Annual Meeting 2019
Nov 26, 2019
CNS Pharmaceuticals Entered $2.0 Million Sublicense Agreement with WPD Pharmaceuticals
Nov 15, 2019
Rigel Receives Positive CHMP Opinion for Fostamatinib Disodium Hexahydrate for Adult Patients with Chronic Immune Thrombocytopenia (ITP) in Europe
Nov 14, 2019
VistaGen Reports Topline Phase 2 Results for AV-101 as an Adjunctive Treatment of Major Depressive Disorder
Nov 13, 2019
Global 1,4-Butanediol (BDO), Polytetramethylene Ether Glycol (PTMEG) & Spandex Market Report 2019-2025 - ResearchAndMarkets.com
Nov 07, 2019
VistaGen Therapeutics Reports Fiscal 2020 Second Quarter Financial Results and Provides Pipeline Overview
Nov 06, 2019
Endoceutics® Receives Health Canada Approval for INTRAROSA®
Oct 29, 2019
Rigel Announces Conference Call and Webcast to Report Third Quarter 2019 Financial Results
Oct 28, 2019
VistaGen Therapeutics Expands European Patent Protection for AV-101 for Treatment of Depression and Dyskinesia associated with Levodopa Therapy for Parkinson's Disease
Oct 23, 2019
Rigel Pharmaceuticals Provides Business Update Prior to Investor & Analyst Call
Oct 18, 2019
Rigel Receives Positive Trend Vote from CHMP for Fostamatinib Disodium Hexahydrate for Adult Patients with Chronic Immune Thrombocytopenia (ITP) in Europe
Oct 16, 2019
Rigel to Host Investor and Analyst Call on October 23, 2019
Oct 08, 2019
VistaGen Therapeutics Announces Last Patient Completes Dosing in the ELEVATE Phase 2 Clinical Study of AV-101 for Major Depressive Disorder
Sep 23, 2019
Rigel's fostamatinib Enters Phase 3 Clinical Trial in Japan with Kissei Pharmaceuticals for the Treatment of Chronic Immune Thrombocytopenia
Sep 15, 2019
New Interim Data in RRMM Patients With Extramedullary Disease from the Pivotal Phase 2 Horizon-study Presented at International Myeloma Workshop